Form 8-K - Current report:
SEC Accession No. 0001641172-25-013603
Filing Date
2025-06-04
Accepted
2025-06-04 16:05:10
Documents
15
Period of Report
2025-06-04
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 72918
2 GRAPHIC form8-k_001.jpg GRAPHIC 5291
3 EX-3.4 ex3-4.htm EX-3.4 9521
  Complete submission text file 0001641172-25-013603.txt   268968

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lpcn-20250604.xsd EX-101.SCH 3014
5 XBRL LABEL FILE lpcn-20250604_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE lpcn-20250604_pre.xml EX-101.PRE 22358
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3802
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 251023099
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)